We caught up with Professor Peter Clemmensen (University Heart Center Hamburg, Hamburg, Germany) to discuss the recent ESC Guidelines update for non-ST elevation myocardial infarction (N-STEMI) and how these may affect outcomes and clinical practice.
Questions
- What are the major unmet needs in the management of acute myocardial infarction in patients presenting without ST-segment elevation? (0.22)
- How do non-ST elevation myocardial infarction (N-STEMI) outcomes vary across Europe? (1.31)
- Could you give us an overview of what’s new in the guidelines? (2.35)
- What will be the major impact of these guidelines on clinical practice? (5.40)
- What practical advice would you like to share with physicians managing N-STEMI in their patients? (7.00)
Speaker disclosures: Professor Peter Clemmensen has previously or currently been involved in research contracts, consulting, speakers bureau or received research and educational grants from Abbott, AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli-Lilly, Evolva, Fibrex, Janssen, Merck, Myogen, Medtronic, Mitsubishi Pharma, The Medicines Company, Nycomed, Organon, Pfizer, Pharmacia, Regado, Sanofi, Searle, Servier and ViFor Pharma.
Support: Commissioned, edited and funded by Touch Medical Media.
Filmed during a remote video call with Professor Peter Clemmensen, September 2020.
